biostudies-literatureYuan HAnhui Medical UniversityNational Natural Science Foundation of ChinaChina Postdoctoral Science FoundationScientific Research Foundation of Education Department of Anhui Province of China2997https://www.ebi.ac.uk/biostudies/studies/S-EPMC11757752biostudies-literatureUnknown15(1)Although tamoxifen is commonly utilized as adjuvant therapy for Estrogen Receptor alpha (ERα)-positive breast cancer patients, approximately 30-50% of individuals treated with tamoxifen experience relapse. Therefore, it is essential to investigate additional factors besides ERα that influence the estrogen response. In this study, cross-analysis of databases were performed, and the results revealed a significant association between LINC00626 and ERα signaling as well as increased expression levels of this gene in tamoxifen-resistant cells. LINC00626 is a novel ERα-regulated long non-coding RNA (lncRNA) that has not yet been examined for its potential contribution to endocrine therapy resistance. This study revealed that the upregulation of LINC00626 in breast cancer was associated with poorScientific reportsLINC00626 drives tamoxifen resistance in breast cancer cells by interaction with UPF1.PMC117577522022M7201982022xkj023823033292023AH053180Zhou LHu WYang MYuan HfalseLINC00626 drives tamoxifen resistance in breast cancer cells by interaction with UPF1.Although tamoxifen is commonly utilized as adjuvant therapy for Estrogen Receptor alpha (ERα)-positive breast cancer patients, approximately 30-50% of individuals treated with tamoxifen experience relapse. Therefore, it is essential to investigate additional factors besides ERα that influence the estrogen response. In this study, cross-analysis of databases were performed, and the results revealed a significant association between LINC00626 and ERα signaling as well as increased expression levels of this gene in tamoxifen-resistant cells. LINC00626 is a novel ERα-regulated long non-coding RNA (lncRNA) that has not yet been examined for its potential contribution to endocrine therapy resistance. This study revealed that the upregulation of LINC00626 in breast cancer was associated with poor2025-01-01T00:00:00Z2025 Jan2026-06-02T06:50:29.995Z2025-04-03T23:21:18.713ZS-EPMC117577523984899210.1038/s41598-025-86287-2